Aptorum logo
Aptorum
APM | NASDAQ
Chart Builder DCF Calculator
$8.26
-$1.44 (-14.85%)
At close: Aug 05, 2026, 03:39 PM ET

Aptorum Company Profile

Company profile explained

Company Profile

Aptorum Group Limited, through its subsidiaries, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small molecule, which is in phase 1 clinical trial for the treatment of bacterial infections, such as staphylococcus aureus, mycobacterium tuberculosis, and pseudomonas aeruginosa; and RPIDD, a liquid biopsy rapid pathogen diagnostic which is in preclinical trial to treat pathogen molecular diagnostics. The company also develops SACT-COV19, a repurposed small molecule which is in preclinical trial for the treatment of coronavirus disease; SACT-2 and SACT-3; ALS-1, a small molecule which is in preclinical trial to treat bacterial infections caused by staphylococcus aureus, including methicillin-resistant staphylococcus aureus (MRSA); and ALS-2/3, a small molecule which is in preclinical trial for the treatment of gram+ve bacterial infections. In addition, it is developing NLS-1, which is in preclinical trial for the treatment of endometriosis; DLS-1+2, which is in preclinical trial to treat NSCLC with mutation; DLS-3, which is in preclinical trial to treat autoimmune disease; CLS-1, a macromolecule, which is in preclinical trial to treat obesity; and CLS-1 and CLS-3. Further, the company offers NativusWell DOI (NLS-2), a dietary supplement for women undergoing menopause; and provides management services. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.

Key Executives

Name Position
Chung Yuen Huen Founder, Chief Executive Officer & Executive Director
Kwok Kuen Wong Head of Finance

Latest SEC Filings

Date Type Title
Oct 02, 2026 S-3/A [Amend] Filing
Sep 18, 2026 S-3/A [Amend] Filing
Sep 14, 2026 8-K Current Report
Sep 04, 2026 8-K Current Report
Aug 28, 2026 RW Filing
Aug 28, 2026 S-3 Filing
Aug 21, 2026 8-K/A [Amend] Current Report
Aug 21, 2026 8-K Current Report
Aug 13, 2026 3 Filing
Aug 13, 2026 3 Filing
View All SEC Filings ➞
Aptorum
Aptorum logo
Country United States
IPO Date Dec 18, 2018
Industry Biotechnology
Sector Healthcare
Employees 2
CEO Ian Huen

Contact Details

116 Village Boulevard Princeton, New Jersey 08540 United States

Stock Details

Ticker Symbol APM
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001734005
CUSIP Number G6096M122
ISIN Number KYG6096M1226
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.